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Introduction 
Low levels of  long-chain (LC) omega-3 (n-3) fatty acids (FA) in 
tissues are a marker of  increased risk for coronary heart disease 
[1]. Though, results from a recent meta-analysis of  the role of  
n-3 FA supplementation on major cardiovascular outcomes did 
not support a causal link between n-3 FA intakes and low risk 
of  all-cause mortality, cardiac death, sudden death, myocardial 
infarction, or stroke based on relative and absolute measures of  
association [2]. Results from this meta-analysis remain controver-
sial, as the mean doses of  n-3 FAs used in several randomized 
clinical trials included in the analysis were lower than the doses of  
2-4 grams/day of  n-3 FAs recommended by the American Heart 
Association for patients with hypertriglyceridemia [3]. 
Incorporation of  n-3 FAs into transport, functional and storage 
pools occur in a dose- and time-dependent manner [4]. Eicosap-
entaenoic acid (EPA) and docosahexaenoic acid (DHA) influence 
the physical nature of  cell membranes, thus directly impacting 
on membrane protein-mediated responses, lipid mediators, cell 
signalling, and gene expression [5]. Moreover, an increased intake 
of  polyunsaturated FAs of  the n-3 series, in particular EPA and 
DHA, may have a favourable effect on serum lipids. These n-3 
FAs act both directly by substituting arachidonic acid (AA) in cell 
membranes and by inhibiting AA metabolism [6]. The inhibition 
of  AA metabolism favours the incorporation of  n-3 FAs into cell 
membranes.
Any modifications in dietary fat intake affect the composition of  
cell membranes. Thus, principal component analysis (PCA) may 
be useful to show which variables are correlated with one another, 
possibly measuring the same construct. PCA allows reducing the 
number of  observed variables, in the present study plasma phos-
pholipid (PPL) FAs, into a smaller number of  components that 
will account for most of  the variance in comparison to one meas-
Abstract
The objective of  the present study was to test for associations between changes in fatty acids (FAs) and changes in plasma 
triglyceride (TG) levels after an n-3 FA supplementation and to test whether SNPs from the FADS gene cluster were associ-
ated with plasma FA levels or with specific FA patterns. A total of  210 subjects completed a 2-wk run-in period followed by 
6-wk supplementation with 5g/d of  fish oil. FA profiles of  plasma phospholipids (PPLs) were obtained and 19 SNPs from 
the FADS gene cluster were genotyped. Principal component analysis was conducted and scores were calculated. There was 
an increase in EPA, DPA and DHA levels in PPLs as well as a decrease in ALA and all n-6 FA levels after the supplementa-
tion. Factor analysis suggested 4 post-n-3 FA supplementation patterns. Changes in AA, ALA, DGLA, as well as changes 
in total n-3 and omega-6 FAs in absolute quantities of  FAs were all associated with a change in TG levels whereas the cor-
relation remained significant only for AA and DGLA when FAs were expressed as percentage of  total FAs. Several SNPs 
from the FADS gene cluster were associated with post-supplementation FA levels. These results suggest that FAs alone or 
regrouped in factors could play a role in modulating plasma TG levels after fish oil supplementation. SNPs from the FADS 
gene cluster interact with both FAs and/or factors to modulate TG levels.
Keywords: Omega-3; Omega-6; EPA; DHA; Principal Component Analysis; Plasma Phospholipids; FADS; Genotype; 
Polymorphisms.
Special Issue on "Nutrigenetics"
Vohl MC et al., (2015) Changes in Plasma Phospholipid Fatty Acid Patterns and their Impact on Plasma Triglyceride Levels Following Fish Oil Supplementation. Int J 
Food Sci Nutr Diet. S2:001 1-10. 2
 http://scidoc.org/IJFS.php
ured by FA itself. In the present study, PCA were made after the 
n-3 FA supplementation to see if  the supplementation itself  may 
affect correlations between FAs.
Recent studies suggested that plasma n−6 and n−3 FA levels are 
associated with several common single nucleotide polymorphisms 
(SNPs) of  the fatty acid desaturase (FADS) gene cluster [7-9].Ge-
nome-wide association studies (GWAS) have shown that SNPs 
of  genes encoding enzymes involved in LC polyunsaturated FA 
metabolism affect plasma FA levels [10-12]. Genetic susceptibil-
ity may lead to a defect in the activity of  specific enzymes named 
desaturases and elongases, and could possibly lead to the develop-
ment of  low-grade inflammation, insulin resistance, type 2 dia-
betes mellitus, metabolic syndrome, hypertension, atherosclerosis 
and ischemic heart disease [13].
We have previously reported that SNPs within the FADS gene 
cluster are associated with plasma desaturase activities after n-3 
FA supplementation [14]. FADS1 and FADS2 genes encode re-
spectively for two desaturases: δ-5 desaturase (D5D) and δ-6 de-
saturase (D6D) [7]. The D5D and D6D, responsible for double 
bonds formation in the n-3 FA pathways, have been associated 
with differences in FA composition of  plasma [15], erythrocyte 
membranes [9] and adipose tissue [15]. 
The objectives of  the present study was to test for associations 
between changes in percentage of  FAs alone or regrouped as fac-
tors with changes in plasma triglyceride (TG) levels after the n-3 
FAs supplementation and to test whether SNPs from the FADS 
gene cluster were associated with plasma FA levels or with spe-
cific FA patterns derived from PCA after the supplementation. 
Methods
Study Population
A total of  254 subjects from the greater Quebec City metropoli-
tan area were recruited between September 2009 and December 
2011 through advertisements in local newspapers as well as by 
electronic messages sent to university students/employees. Sub-
jects had to be aged between 18 and 50 years old with a body 
mass index (BMI) between 25 and 40 kg/m². They had to be non-
smokers and free of  any thyroid or metabolic disorders requir-
ing treatment. Participants were excluded if  they had taken n-3 
FA supplements for at least 6 months prior to the beginning of  
the study. However, only 210 subjects completed the interven-
tion protocol and blood lipid profile pre-and/or post-supplemen-
tation are missing for two participants. Statistical analyses were 
then performed on 208 individuals. The ethics committees of  
Laval University Hospital Research Center and Laval University 
approved the experimental protocol. This trial was registered at 
clinicaltrials.gov as NCT01343342.
Study Design and Diets
The complete study design has been previously reported [16]. 
Briefly, subjects followed a run-in period of  two weeks where 
a trained registered dietitian gave individual dietary instructions. 
Recommendations were drawn from the Canada’s Food Guide to 
Healthy Eating [17]. After a 2-week run-in period, each partici-
pant received a bottle containing capsules of  n-3 FAs (Ocean 
Nutrition, Nova Scotia, Canada) covering the following six-week 
period. They had to take 5 capsules per day, which gave them a 
total of  3-3.3g of  n-3 FAs (1.9-2.2g EPA and 1.1g DHA) per 
day. Subjects had to report any deviations that may have occurred 
during the protocol. They also had to write their alcohol and fish 
consumption on a log sheet. Before each phase of  the study, sub-
jects received written and oral dietary instructions by a registered 
dietitian.
SNPs Selection and Genotyping
SNPs in FADS1, FADS2, and FADS3 were identified using the 
International Hap Map Project SNP database, based on the Na-
tional Center for Biotechnology Information (NCBI) B36 assem-
bly Data Rel 28. phase II + III, build 126. The FADS gene cluster 
is made of  three genes that are located very close to each other 
on chromosome 11. Because of  the head-to-head orientation of  
FADS1 and FADS2 and the tail-to-tail orientation of  FADS2 
and FADS3, we added 500 kilo-base pairs (kbp) downstream of  
FADS1 and 2500 kbp upstream of  FADS3 to cover promoter 
regions. Intergenic areas were also covered. Gene Tagger proce-
dure in Haploview V4.2 was used to determine tag SNPs (tSNPs) 
using a minor allele frequency (MAF) ≥ 3% and pairwise tagging 
(r2≥0.8). Subsequently, we examined linkage disequilibrium (LD) 
out of  the nineteen SNPs of  the FADS gene cluster area using 
the LD Plot procedure in Haploview V4.2. The SIGMA Gen-
Elute Gel Extraction Kit (Sigma-Aldrich Co. St.Louis. Missouri. 
USA) has been used to extract genomic DNA. Selected SNPs of  
the FADS gene cluster (rs174456, rs174627, rs482548, rs2072114, 
rs12807005, rs174448, rs2845573, rs7394871, rs7942717, 
rs74823126, rs174602, rs498793, rs7935946, rs174546, rs174570, 
rs174579, rs174611, rs174616 and rs968567) have been geno-
typed using validated primers and TaqMan probes (Thermo Fish-
er Scientific, Waltham, MA, USA). DNA was mixed with TaqMan 
Universal PCR Master Mix (Thermo Fisher Scientific, Waltham, 
MA, USA), with a gene-specific primer and with probe mixture 
(predeveloped TaqMan SNP Genotyping Assays; Thermo Fisher 
Scientific, Waltham, MA, USA) in a final volume of  10μl. Geno-
types were determined using a 7500 RT-PCR System and analyzed 
using ABI Prism SDS version 2.0.5 (Thermo Fisher Scientific, 
Waltham, MA, USA).
Biochemical Parameters measurements
Fasting insulin concentrations were measured by radioimmu-
noassay with polyethylene glycol separation [18]. Fasting glucose 
concentrations were enzymatically measured [19]. Plasma C-re-
active protein (CRP) was measured by nephelometry (Prospec 
equipment Behring) using a sensitive assay, as described previ-
ously [20]. Plasma total cholesterol and TG concentrations were 
measured using enzymatic assays [21]. The high-density lipopro-
tein cholesterol fraction was obtained after precipitation of  very 
low-density lipoprotein and low-density lipoprotein particles in 
the infranatant with heparin manganese chloride [22]. Low-den-
sity lipoprotein cholesterol was calculated with the Friedewald 
formula [23].
Measurement of  FA Composition in Plasma Phospholipids
Blood samples were collected from an antecubital vein into vacu-
tainer tubes containing EDTA after 12 hours overnight fast and 
48 hours alcohol abstinence. Plasma was separated by centrifuga-
tion at 500 g for 6 min and stored at –80°C for subsequent analy-
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ses. Plasma lipids were extracted with chloroform:methanol (2:1, 
by volume) according to a modified Folch method [24]. FA com-
position of  PPLs was determined by gas chromatography. Total 
phospholipids were isolated with isopropyl ether:acetic acid (96:4) 
by thin layer chromatography [25]. Isolated PPLs were then meth-
ylated [26]. FA profiles were obtained after methylation in metha-
nol/benzene 4:1 (v/v) [26] and capillary gas chromatography 
using a temperature gradient on a HP5890 gas chromatograph 
(Hewlett Packard, Toronto, Canada) equipped with a HP-88 capil-
lary column (100m x 0.25 mm i.d. x 0.20µm film thickness; Agi-
lent Technologies, Palo Atto, CA) coupled with a flame ionization 
detector (FID). Helium was used as carrier gas (split ratio 1:80). 
FA were identified according to their retention time, using the 
following standard mixtures as a basis for comparison: the FAME 
37 mix (Supelco Inc., Bellefonte, PA) and the GLC-411 FA mix 
(NuChek Prep Inc, Elysian, MN), as well as the following methyl-
ated FAs C22:5n-6 (Larodan AB, Malmö, Sweden) and C22:5n-3 
(Supelco Inc., Bellefonte, PA).
Principal Component Analysis (PCA)
Variables with abnormal distribution where logarithmically 
transformed before further analyses. Principal factor analy-
sis was conducted in SAS v9.3 (SAS Institute Inc., Cary, North 
Carolina, USA) using the FACTOR procedure. Measured FAs 
(all-cis-8,11,14-eicosatrienoic acid (C20:3n-6, DGLA), docosa-
tetraenoic acid (C22:4n-6), 4,7,10,13,16-docosapentaenoic acid 
(C22:5n-6), docosanoic acid (C22:0), tetracosanoic acid (C24:0), 
eicosanoic acid (C20:0), cis-9-octadecenoic acid (C18:1n-9), do-
cosahexaenoic acid (C22:6n-3, DHA), 7,10,13,16,19-docosapen-
taenoic acid (C22:5n-3), eicosapentaenoic acid (C20:5n-3, EPA), 
octadecadienoic acid (C18:2n-6, LA), trans-11-octadecenoic acid 
(C18:1 trans-11), cis-6-octadecenoic acid (C18:1), trans-9-hexade-
cenoic acid (C16:1 trans-9), hexadecanoic acid (C16:0), hexadece-
noic acid (C16:1), octadecanoic acid (C18:0), tetradecanoic acid 
(C14:0), octadecatrienoic acid (C18:3n-3, ALA), octadecenoic 
acid (C18:1n-7), all-cis-5, 8, 1, 14-eicosatetraenoic acid (C20:4n-6, 
AA), cis-11-eicosenoic acid (C20: 1n-9), eicosadienoic acid 
(C20:2n-6), cis-9-tetradecenoic acid (C14:1), cis-15-tetracosenoic 
acid (C24:1n-9), trans-9-octadecenoic acid (C18:1 trans-9) and 
eicosatrienoic acid (C20:3)) pre- and post-supplementation were 
analysed separately in order to develop components. To deter-
mine the number of  factors to retain, components with Eigenval-
ue ≥ 2 at Screen test were considered. FAs with positive loadings 
contribute to the pattern; FAs with negative loadings are inversely 
associated with the pattern. In post-supplementation, 4 factors 
were considered (Figure 1). Looking at the rotated solution (rota-
tion method: Varimax), FAs with absolute factor loadings ≥ 0.5 
were regarded as significant contributors to the pattern. Each par-
ticipant was given a score for the 4 post-supplementation factors. 
These scores were calculated from the sum of  phospholipid FA 
concentrations multiplied by their matching scoring coefficients. 
These scores reflect the degree of  each participant PPL FAs con-
forming to a FA pattern.
Statistical Analysis
All genotype distributions were tested for any deviation from 
Hardy-Weinberg equilibrium (HWE) using the ALLELE proce-
dure in S.A.S Genetics v9.3 (S.A.S Institute Inc., Cary, North Car-
olina, USA). Significance testing for linkage disequilibrium (LD) 
coefficient D was obtained using a chi-square test, likelihood ratio 
and Fisher exact test (p≤0.01). All other statistical analyses were 
carried out using S.A.S statistical software v9.3 (S.A.S Institute 
Inc., Cary, North Carolina, USA). Normal distribution was eval-
uated looking at the box-plot as well as skewness and kurtosis 
ranges for normal distribution. When needed, variables non-nor-
mally distributed were log10-transformed. A general linear model 
(GLM) was used to test for associations between PPL FAs and 
SNPs from the FADS gene cluster after an n-3 FA supplementa-
tion. GLM was adjusted for baseline PPL FAs levels for analyses 
involving post-supplementation data. For some SNPs, heterozy-
gotes and homozygotes for the minor allele were grouped if  the 
genotype frequency of  the homozygotes for the minor allele was 
Figure 1. Post-n-3 FA supplementation patterns derived from PCA. 
PCA revealed four post-supplementation phospholipid fatty acid factors. Factor 1 included all-cis-8,11,14-eicosatrienoic acid (C20:3n-6, 
DGLA), docosatetraenoic acid (C22:4n-6), 4,7,10,13,16-docosapentaenoic acid (C22:5n-6) and eicosapentaenoic acid (C20:5n-3, EPA). 
Factor 2 included docosanoic acid (C22:0), tetracosanoic acid (C24:0), eicosanoic acid (C20:0) and cis-9-octadecenoic acid (C18:1n-9). 
Factor 3 included docosahexaenoic acid (C22:6n-3, DHA), docosapentaenoic acid (C22:5n-3), eicosapentaenoic acid (C20:5n-3, EPA) 
and octadecadienoic acid (C18:2n-6, LA). Factor 4 included trans-11-octadecenoic acid (C18:1 trans-11), cis-6-octadecenoic acid (C18:1) 
and trans-9-hexadecenoic acid (C16:1 trans-9). 
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under 5%. Statistical significance was defined as p ≤ 0.05.
Results
SNPs within the FADS gene cluster are shown in Table 1. All 
SNPs were in HWE except rs7935946, located in an intron of  
FADS2. Thus, this SNP was not considered for further analyses. 
Daily energy intakes were calculated by a food frequency ques-
tionnaire validated for healthy French-Canadians [27] and are pre-
sented in Table 2. After the supplementation, carbohydrates, satu-
rated fats, proteins and PUFA intakes were significantly different 
from the pre n-3 FA period (p=0.0005; p=0.0008; p=0.02; and 
p=0.003, respectively). Subjects have significantly decreased their 
fasting plasma TG levels (-11.9%, p<0.0001) and have slightly in-
creased their fasting glucose levels (+2.4%, p=0.02) (Table 2).
Changes in plasma phospholipid FAs following an n-3 FA 
supplementation
Changes in PPL FAs (in percentage of  total FAs) following a 
6-week n-3 FA supplementation are reported in Table 3. Briefly, 
there was an increase in EPA, DPA and DHA levels in PPLs as 
well as a decrease in ALA and all n-6 FA levels after the supple-
mentation (p≤0.0002, for all). A significant decrease was observed 
for all MUFA levels in PPLs except for cis-9-tetradecenoic acid 
(C14: 1) and for cis-15-tetracosenoic acid (C24: 1n-9) for which 
non-significant increases were observed. For SFA levels, small, 
but significant increases were observed in PPLs with> 18-carbon 
atoms FAs (p< 0.007 for all). Factor analysis suggested 4 post-n3 
FA supplementation patterns. Figure 1 shows the composition of  
the 4 main post-supplementation factors. A factor loading ≥ 0.5 
indicates a strong positive association with the FAs profile where-
as a factor loading ≤ -0.5 indicates a strong inverse association 
with the FAs profile. Factor 1 included all-cis-8,11,14-eicosatrie-
noic acid (C20:3n-6, DGLA), docosatetraenoic acid (C22:4n-6), 
4, 7, 10, 13, 16-docosapentaenoic acid (C22:5n-6) and eicosapen-
taenoic acid (C20:5n-3, EPA). Factor 2 included docosanoic acid 
(C22:0), tetracosanoic acid (C24:0), eicosanoic acid (C20:0) and 
cis-9-octadecenoic acid (C18:1n-9). Factor 3 included docosahex-
aenoic acid (C22:6n-3, DHA), 7, 10, 13, 16, 19-docosapentaenoic 
acid (C22:5n-3), eicosapentaenoic acid (C20:5n-3, EPA) and octa-
decadienoic acid (C18:2n-6, LA). Factor 4 included trans-11-octa-
decenoic acid (C18:1trans-11), cis-6-octadecenoic acid (C18:1) and 
Table 1. Characteristics of  SNPs within the FADS gene cluster.
dbSNP No.1 Sequence2 Position Alleles AA CC CA CG CT GA GG GT TT MAF
n3(%)
FADS1
rs174546 TGC[C/T]
TTG
3′ UTR C/T 103 (49.8) 86 (41.2) 10 (9.1) T=33.0
FADS2
rs482548 CAC[C/T]
GTG
3′ UTR C/T 161 (77.8) 40 (19.3) 6 (2.9) T=3.9
rs2072114 TTC[A/G]
GGT
Intron A/G 167 (79.9) 38 (18.2) 4 (1.9) G=20.0
rs2845573 TCA[C/T]
GTT
Intron A/G 177 (84.7) 30 (14.4) 2 (1.0) G=15.3
rs174602 CCC[A/G]
TCC
Intron T/C 9 (4.3) 59 (28.2) 141 (67.5) C=39.2
rs498793 AAC[A/G]
CAG
Intron C/T 62 (9.8) 99 (71.7) 43 (18.6) T=31.3
rs174570 TGA[C/T]
GTA
Intron C/T 159 (76.4) 46 (22.1) 3 (1.4) T=23.5
rs174579 TTT[C/T]
CAG
Intron C/T 127 (61.1) 78 (37.5) 3 (1.4) T=16.3
rs174611 GGA[C/T]
CCT
Intron T/C 12 (5.7) 84 (40.2) 113 (54.1) C=14.3
rs174616 TCA[C/T]
GTT
Intron A/G 51 (24.4) 158 (51.7) 50 (23.9) A=45.4
rs968567 CGG[A/G]
AGC
5′ UTR G/A 2 (1.0) 63 (30.1) 144 (68.9) T=7.9
FADS3
rs174456 TAC[A/C]
TGG
Intron A/C 102 (48.8) 18 (8.6) 89 (42.6) C=44.3
rs7394871 GAC[A/C]
CCT
Intron C/A 2 (1.0) 181 (86.6) 26 (12.4) A=16.1
rs7942717 ACG[A/G]
GTG
Intron A/G 161 (77.0) 47 (22.5) 1 (0.5) G=8.8
Intergenic regions within the FADS gene cluster
rs174627 CTG[C/T]
GTA
Intergenic G/A 2 (1.0) 48 (23.0) 159 (76.1) A=7.1
rs12807005 ATG[A/G]
ATC
Intergenic G/A 0 (0) 5 (2.4) 204 (97.6) A=1.0
rs174448 TGA[C/T]
TTC
Intergenic A/G 78 (37.5) 109 (52.4) 21 (10.1) G=37.6
rs7482316 CAA[A/G]
CTG
Intergenic A/G 168 (80.4) 39 (18.7) 2 (1.0) G=6.7
1 dbSNP No. from Hap Map Data Rel 28 Phase II+III, August 10 on NCBI b36 Assembly dbSNP b126 database.
2 Genes sequences from dbSNP short genetics variations NCBI reference assembly.
3 Number of  subjects for each genotype.
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Table 2. Pre- and post-supplementation descriptive characteristics (n=208).
Pre-Supplementation Post-Supplementation
(including capsules)
p-values3
Weight (kg)4 81.3 ± 13.9 81.7 ± 14.3 0.83
BMI (kg/m2)2,4 27.8 ± 3.7 27.9 ± 3.9 0.81
Waist circumference (cm)4 93.3 ± 10.5 93.4 ± 10.8 0.93
Daily energy intake
     Energy (Kcal) 2272±590 2143±566 0.08
     Total lipids, (g) 86.5±29.2 86.6±29.8 0.48
     MUFA (g) 30.8±11.8 29.6±12.4 0.13
     PUFA (g) 15.2±6.6 17.1±6.9 0.003
     SFA (g) 29.0±12.0 25.5±10.4 0.0008
     Cholesterol (mg) 303.7±147.4 297.3±169.4 0.41
     Carbohydrates (g) 286.7±78.9 263.4±77.7 0.0005
     Proteins (g) 97.8±30.2 92.6±29.6 0.02
     Alcohol (g) 3.2±6.0 3.2±6.1 0.81
Cardiometabolic risk factors
     Total cholesterol (mmol/L) 4.75± 0.90 4.72± 0.94 0.74
     HDL-cholesterol (mmol/L) 1.44± 0.36 1.47± 0.40 0.28
     LDL-cholesterol (mmol/L) 2.76± 0.81 2.78± 0.85 0.77
Triglycerides (mmol/L)2 1.21± 0.63 1.02± 0.52 <0.0001
     CRP (mg/L)2 1.82± 2.17 1.85± 2.12 0.98
     Glucose (mmol/L) 4.95± 0.46 5.06± 0.49 0.02
     Insulin (ρmol/L)2 87.1± 75.7 83.6± 40.8 0.91
1 Values are means ± SD;
2 Data were log10-transformed;
3 p-values are derived from a repeated measures ANOVA adjusted for the effects of  age, sex and BMI;
4 p-values are derived from a repeated measures ANOVA adjusted for the effects of  age only.
Table 3. Changes in plasma phospholipid fatty acids prior to and after an n-3 FA supplementation.
Plasma phospholipid fatty acids Pre-suppl. Post-suppl. Change (%) p-value1
SFA (% of  total fatty acids)
Tetradecanoic acid (C14:0) 0.38±0.10 0.37±0.10 -2.3 0.18
Hexadecanoic acid (C16:0) 27.73±1.50 27.65±1.41 -0.3 0.21
Octadecanoic acid (C18:0) 13.53±1.29 13.97±1.36 3.2 <0.0001
Eicosanoic acid (C20:0) 0.62±0.11 0.64±0.12 3.4 0.007
Docosanoic acid (C22:0) 1.79±0.28 1.85±0.31 2.9 0.0006
Tetracosanoic acid (C24:0) 1.43±0.25 1.50±0.27 4.5 <0.0001
MUFA (% of  total fatty acids)
cis-9-tetradecenoic acid (C14:1) 0.11±0.10 0.12±0.10 5.3 0.42
Hexadecenoic acid (C16:1) 0.52±0.19 0.45±0.16 -14.3 <0.0001
trans-9-Hexadecenoic acid (C16:1 trans-9) 0.16±0.10 0.13±0.10 -15.5 0.002
cis-6-Octadecenoic acid (C18:1) 0.07±0.10 0.05±0.09 -30.4 0.003
cis-9-Octadecenoic acid (C18:1n-9) 8.58±1.00 7.99±1.18 -6.8 <0.0001
Octadecenoic acid (C18:1n-7) 1.33±0.21 1.29±0.17 -3.2 0.006
trans-9-Octadecenoic acid (C18:1 trans-9) 0.02±0.06 0.02±0.05 -34.4 0.07
trans-11-Octadecenoic acid (C18:1 trans-11) 0.12±0.11 0.10±0.11 -13.6 0.06
cis-11-eicosenoic acid (C20:1n-9) 0.10±0.12 0.08±0.09 -24.0 0.004
cis-15-tetracosenoic acid (C24:1n-9) 2.57±0.56 2.67±0.62 3.9 0.08
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trans-9-hexadecenoic acid (C16:1 trans-9).
Table 4 shows the differences in post-supplementation FA pat-
tern scores between positive (delta TG < 0) and negative (delta 
TG ≥ 0) responders based on their plasma TG levels after a 6-wk 
fish oil supplementation. Overall, there appears to be a tendency 
to show FA pattern scores in the opposite direction between posi-
tive and negative responders and this difference is significant for 
factor 2 (p=0.02).
Table 5 shows Pearson correlation coefficients between change in 
TG levels (TG post- minus TG pre-supplementation in mmol/L) 
and changes in FAs alone or regrouped as factors after the 6-week 
n-3 FA supplementation. Changes in AA, ALA, DGLA, as well 
as changes in total n-3 and n-6 FAs in absolute quantities of  FAs 
(model 1) were all associated with a change in TG levels in the 
total cohort (p<0.04, for all) whereas the correlation remained 
significant only for AA and DGLA when FAs were expressed as 
percentage of  total FAs (model 2). When subjects are stratified in 
negative or positive responders on the basis of  plasma TG levels, 
a positive correlation was observed between change in TG levels 
and the change in DGLA in absolute quantities in both groups 
(model 1). When changes were expressed as percentage of  to-
tal FAs, there was a positive and significant correlation observed 
between the change in TG levels and the change in DGLA only 
for negative responders (model 2). In positive responders, percent 
changes in EPA, DHA and in Factor 1 were correlated to the 
change in plasma TG levels (model 2).
In a general linear model adjusted for the effects of  age, sex, BMI 
and baseline FA levels, several SNPs from the FADS gene cluster 
were associated with post-supplementation FA levels, especially 
with ALA levels (7 SNPs), AA levels (2 SNPs) and EPA levels 
(2 SNPs) as shown in Table 6. Associations between SNPs from 
the FADS gene cluster and post-supplementation factors derived 
from PCA (1 SNP associated with Factor 1 and 2 SNPs associated 
with Factors 2, 3 and 4) were also observed using the same statisti-
cal model, but with post-supplementation factors as the depend-
ent variable (Table 6). 
Discussion
In this study, we tested whether PPL FAs individually or re-
grouped as FA patterns were associated with a change in TG lev-
PUFA (% of  total fatty acids)
     Total n-6
Octadecadienoic acid (C18:2n-6, LA) 19.71±2.08 17.69±2.22 -10.2 <0.0001
Eicosadienoic acid (C20:2n-6) 0.32±0.07 0.27±0.06 -15.4 <0.0001
all-cis-8,11,14-eicosatrienoic acid (C20:3n-6, 
DGLA)
3.29±0.74 2.38±0.60 -27.6 <0.0001
all-cis-5,8,1,14-Eicosatetraenoic acid 
(C20:4n-6, AA)
11.05±1.74 9.74±1.44 -11.9 <0.0001
          Docosatetraenoic acid (C22:4n-6) 0.35±0.07 0.19±0.09 -46.2 <0.0001
4,7,10,13,16-Docosapentaenoic acid 
(C22:5n-6)
0.28±0.12 0.10±0.10 -65.1 <0.0001
     Total n-3
Octadecatrienoic acid (C18:3n-3, ALA) 0.18±0.15 0.14±0.12 -22.3 0.0002
Eicosapentaenoic acid (C20:5n-3, EPA) 1.12±0.52 4.10±1.28 266.9 <0.0001
7,10,13,16,19-Docosapentaenoic acid 
(C22:5n-3, DPA)
0.96±0.23 1.39±0.31 44.0 <0.0001
Docosahexaenoic acid (C22:6n-3, DHA) 3.53±0.77 5.03±0.86 42.6 <0.0001
 Values are means±SD expressed as percentage of  total fatty acids.  
1p-values are from a paired Student’s T-Test.
Table 4. Differences in post-supplementation FA pattern scores between positive and negative responders after a 6-wk fish 
oil supplementation.
Post-supplementation factor scores (n=208)
P1ΔTG (n=60, nega-tive responders)
ΔTG (n=148, positive re-
sponders)
Mean ± SD Mean ± SD
Factor 1 0.13 ± 0.96 -0.05 ± 1.02 0.21
Factor 2 -0.24 ± 0.91 0.10 ± 1.02 0.02
Factor 3 0.04 ± 1.20 -0.02 ± 0.86 0.67
Factor 4 -0.05 ± 1.04 0.02 ± 0.99 0.63
1 ANOVA adjusted for age, sex and BMI;
Negative responders have a ΔTG ≥ 0; 
Positive responders have a ΔTG  < 0. 
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Table 5. Pearson correlations between relative change in plasma TG levels and relative changes in FAs alone or regrouped 
as factors after a 6-week fish oil supplementation.
ΔTG (n=60, negative re-
sponders)
ΔTG (n=148, positive 
responders)
ΔTG (n=208)
Model 1 Model 2 Model 1 Model 2 Model 1 Model 2
Factor 1 r=0.19 r=-0.25 r=-0.09
p=0.14 p=0.003 p=0.22
Factor 2 r=-0.21 r=0.10 r=-0.07
p=0.11 p=0.22 p=0.32
Factor 3 r=0.008 r=-0.15 r=-0.06
p=0.95 p=0.07 p=0.37
Factor 4 r=0.13 r=0.06 r=0.04
p=0.34 p=0.50 p=0.58
ΔEPA r=-0.01 r=-0.06 r=0.13 r=0.17 r=0.11 r=0.06
p=0.94 p=0.68 p=0.12 p=0.04 p=0.11 p=0.43
ΔDHA r=0.09 r=0.02 r=-0.05 r=-0.18 r=0.12 r=-0.09
p=0.49 p=0.89 p=0.53 p=0.03 p=0.09 p=0.20
ΔAA r=0.04 r=-0.02 r=0.24 r=-0.04 r=0.24 r=-0.17
p=0.76 p=0.89 p=0.004 p=0.63 p=0.0006 p=0.01
ΔALA r=-0.02 r=-0.03 r=0.17 r=0.12 r=0.15 r=0.07
p=0.90 p=0.82 p=0.04 p=0.14 p=0.04 p=0.28
ΔDGLA r=0.32 r=0.32 r=0.27 r=0.08 r=0.41 r=0.24
p=0.02 p=0.01 p=0.001 p=0.31 p<0.0001 p=0.0006
Δ total n-3 FAs r=0.04 r=-0.02 r=0.09 r=0.08 r= 0.16 r=0.03
p=0.75 p=0.88 p=0.30 p=0.34 p=0.02 p=0.62
Δ total n-6 FAs r=0.15 r=0.06 r=0.24 r=-0.13 r=0.33 r=-0.12
p=0.27 p=0.63 p=0.04 p=0.12 p<0.0001 p=0.08
 Pearson correlations with partials for age, sex and BMI. 
Model 1 -> Correlations with changes in FA concentrations.
Model 2 -> Correlations with changes in FAs expressed as % of  total FAs. 
Negative responders have a ΔTG ≥ 0; 
Positive responders have a ΔTG  < 0. 
Table 6. Associations of  SNPs within the FADS gene cluster with plasma phospholipid fatty acids AFTER a 6-week n-3 FAs 
supplementation.
Fatty acids Post-supplementation factors derived 
from PCA**Omega-6 fatty acids* Omega-3 fatty acids*
18:2n-6 
(LA)
20:2n-6 20:3n-6 
(DGLA)
20:4n-6 
(AA)
22:4n-6 22:5n-6 18:3n-3 
(ALA)
20:5n-3 
(EPA)
22:5n-3 
(DPA)
22:6n-3 
(DHA)
Factor 1 Factor 2 Factor 3 Factor 4
FADS1
rs174546 -- 0.04 -- 0.06 -- -- 0.02 -- -- -- -- 0.03 -- --
FADS2
rs482548 -- -- -- -- -- -- -- -- -- -- -- -- -- --
rs2072114 -- -- -- 0.06 -- -- 0.04 -- -- -- -- -- -- --
rs2845573 -- -- -- 0.03 -- -- 0.007 -- -- -- -- -- -- --
rs174602 -- -- -- -- -- -- -- 0.05 0.01 -- -- -- 0.01 --
rs498793 -- -- -- 0.007 -- -- -- 0.02 -- -- -- -- -- --
rs174570 -- -- -- 0.09 -- -- -- -- -- -- -- -- -- --
rs174579 -- -- -- -- -- -- -- -- -- -- -- -- -- --
rs174611 -- -- -- -- -- -- 0.003 -- -- -- -- -- -- --
rs174616 -- -- -- -- -- -- 0.006 -- -- -- -- -- -- --
rs968567 -- -- -- -- -- -- 0.03 -- -- -- -- -- 0.02 --
FADS3
rs174456 -- -- -- -- -- -- -- -- -- -- -- -- -- --
rs7394871 -- -- -- -- -- -- -- -- -- -- -- -- -- 0.006
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els following an n-3 FA supplementation and whether SNPs from 
the FADS gene cluster influence changes in PPL FAs and FA 
patterns. To our knowledge, this is the first study to investigate 
the effects of  FADS SNPs on FA profiles derived from factor 
analysis after a supplementation with high doses of  n-3 FAs. 
Despite Rizos et al. (2012) have had difficulty demonstrating the 
causality link between n-3 FA intakes and lower risk of  all-cause 
mortality, Hartweg et al. have conducted a systematic review in-
cluding 23 randomized clinical trials and have shown that n-3 FAs 
exert beneficial effects on CVD risk factors such as plasma TG 
and VLDL- cholesterol levels with no adverse effects of  the inter-
vention [2, 28]. There is a growing body of  evidence underlining 
the importance of  the FA composition of  membranes in health 
and disease. For instance, higher plasma levels of  DHA are as-
sociated with a more favorable CVD risk profile [29] and higher 
plasma levels of  EPA are inversely associated with the risk of  
major coronary events [30]. A recent review by Kaur et al. (2011) 
suggested that n-3 DPA may also have potential beneficial prop-
erties on metabolic health [31]. 
FA patterns can be altered by factors known to modulate lipid me-
tabolism such as visceral obesity, insulin resistance and inflamma-
tion [32]. In the present study, there were no significant changes in 
BMI, insulin resistance and inflammation-related traits (data not 
shown). However, only results with PCA post-supplementation 
are presented in this paper to better reflect the changes in FA pat-
terns after the intake of  n-3 FA supplements, because FA patterns 
depend largely on dietary fat intake [33, 34]. The lipid profile of  
individuals undertaking a supplementation with n-3 FAs is altered 
as shown by variations in individual FA levels after the supple-
mentation (Table 3). This metabolic signature could provide new 
insights on the role of  groups of  FAs strongly correlated and 
their ability to act as better biomarkers than FA levels alone meas-
ured in PPLs after a supplementation with high doses of  n-3 FAs.
There was a difference in post-supplementation FA pattern scores 
between positive and negative responders with regard to Factor 
2 after a 6-wk fish oil supplementation. Although this difference 
did not remain significant for the other factors, we observed a 
trend with scores going in the opposite direction between positive 
and negative responders, meaning that FA composition of  PPLs 
is probably different among these individuals.The composition 
of  Factor 2 indicates a strong positive correlation between long-
chain and very long chain saturated FAs in addition to a negative 
correlation with oleic acid. In our study, there was a small but 
significant increase of  saturated FAs in PPLs (expressed as % of  
total FAs, Table 3), but not when looking at absolute quantities 
(data not shown). This change observed in plasma TG levels does 
not seem to be related to the activation of  PPAR-α by saturated 
FAs because saturated FAs with ≥20 carbon units failed to bind 
well with any of  the PPARs [35]. The mechanism by which Factor 
2 may be associated with a decrease in plasma TG levels could 
rely on the substrate specificity of  the lipoprotein lipase (LPL) 
depending of  the FA chain length and the degree of  FA satura-
tion. Even if  LPL has a lower affinity for monoacylglycerol that 
contains a saturated acyl group, it has a higher affinity for LC TGs 
vs. medium-chain TGs [36, 37].  
Post-supplementation Factor 1 included long-chain n-6 FAs with 
positive factor loadings as well as EPA with negative factor load-
ings. Moreover, Factor 1 correlates significantly with the change 
in plasma TG levels in positive responders as shown in Table 5 
(r=-0.25, p=0.003). According to these correlation patterns, in-
dividuals with a high positive score (characterized by ↑DGLA, 
↑4,7,10,13,16-Docosapentaenoic acid, ↑docosatetraenoic acid, 
↓EPA) are more likely to be characterized by an increase TG con-
centrations while individuals having a high negative score (char-
acterized by ↓DGLA, ↓4,7,10,13,16-Docosapentaenoic acid, ↓ 
docosatetraenoic acid, ↑EPA) were more likely to display a de-
crease in TG after the 6-week n-3 FA supplementation. Factor 1 
is similar to the product-to-precursor ratio of  EPA to ALA often 
used as a surrogate measure of  desaturase activity [38, 39]. In this 
study, SNP rs12807005 was associated with post-supplementation 
Factor 1. We have previously shown that carriers of  the minor 
allele of  rs12807005 had significantly higher plasma TG levels 
after the supplementation [16]. Moreover, we have shown that 
this SNP could also modulate estimate of  D5D activity follow-
ing fish oil supplementation whereas carriers of  the minor allele 
had a lower D5D activity post-supplementation, often associated 
with adverse profiles of  several metabolic risk factors [14, 40, 41]. 
Altogether, these results suggests that genetic predispositions 
may lead to more or less long-chain FAs conversion depending 
on the genotype and may affect plasma TG response. Interest-
ingly, Lemaitre et al. have shown that minor alleles of  SNPs in 
FADS1 and FADS2 were associated with higher levels of  ALA 
and lower levels of  EPA and DPA, which is in accordance with 
our results showing that SNPs from the FADS gene cluster could 
also modulate FAs levels regrouped as a unique pattern [12]. A 
previous GWAS on our study population has highlighted new loci 
that could possibly explain the difference observed in plasma TG 
response after an n-3 FA supplementation between positive and 
negative responders characterized by delta TG levels < 0 or ≥ 0, 
respectively [42].
Interestingly, factor 3 post-supplementation included DHA (fac-
tor loading: 0.85), DPA (factor loading: 0.76), EPA (factor load-
ing: 0.58) and LA (factor loading: -0.80) meaning that the increase 
of  plasma FAs levels of  DHA, DPA and EPA after the supple-
mentation is highly correlated to a strong decrease in LA levels as 
measured in PPLs. However, this factor was not associated with a 
change in plasma TG levels in this study. 
According to Lemaitre et al., it is estimated that SNPs could ac-
rs7942717 -- -- -- -- -- -- -- -- -- -- -- -- -- --
Intergenic regions within the FADS gene cluster
rs174627 -- -- -- -- -- -- 0.006 -- -- -- -- 0.05 -- --
rs12807005 -- -- 0.04 -- -- -- -- -- -- -- 0.03 -- -- --
rs174448 -- -- -- -- -- -- -- -- -- -- -- -- -- --
rs7482316 -- -- -- -- 0.003 -- -- -- -- -- -- -- -- 0.01
*p-values are from a general linear model adjusted for the effects of  age, sex, BMI and baseline FA levels. 
**p-values are from a general linear model adjusted for the effects of  age, sex, BMI.
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count for 40 to 70% of  the inter-individual variability observed 
in red blood cell (RBC) FAs and that there are shared genetic 
effects that could either be positive or negative between several 
FAs [43]. Thereby, we believed that changes in FA patterns could 
be partly attributable to genetic factors such as SNPs of  the three 
studied genes. This study shows that SNPs from the FADS gene 
cluster may affect the FA composition of  PPLs after the sup-
plementation. Some SNPs are even associated to a specific FA 
pattern, herein named Factors 1, 2, 3 or 4. Previous studies from 
our group have shown that FADS2 gene expression was changed 
after the 6-week n-3 FA supplementation, possibly leading to al-
terations in the metabolic pathways of  n-6 and n-3 FAs because 
of  the involvement of  the D6D [44].
SNPs in FADS1, which catalyzes the biosynthesis of  highly un-
saturated FAs from precursor essential PUFAs, and two other 
members of  the same gene family, FADS2 and FADS3, have 
been previously associated with FA levels (measured in PPLs or 
in RBCs) or with cardiometabolic traits, even at genome-wide sig-
nificance levels [12, 45, 46]. By directing FAs down this metabolic 
pathway, increased activity of  these enzymes may lower circulating 
TG concentrations [47]. Moreover, the use of  D6D twice in the 
conversion of  ALA to DHA in the n-3 FAs pathway and in the 
conversion of  LA to AA implies that this enzyme may play a key 
regulatory role in the PUFA metabolism [48]. Previous data from 
our research group have shown that gene-diet interactions with 
several SNPs from the FADS gene cluster could potentially mod-
ulate the enzyme activities of  desaturases and elongases involved 
in the FA metabolism post-supplementation, possibly leading to 
different FA levels in PPLs [14]. According to Hong et al., SNPs 
from the FADS gene cluster can affect age-associated changes in 
serum phospholipid LC FAs in addition to D5D activity, and oxi-
dative stress in middle-aged non-obese men [49]. A recent GWAS 
of  PUFAs in the InCHIANTI Study have shown that the mutated 
allele of  rs174537 was associated with higher ALA and LA levels 
and lower AA, EPA, DPA and DHA levels [50]. Results from 
that GWAS have been replicated in the GOLDN study, where 
there were significant associations of  rs174537 (in high LD with 
rs174546, r2=0.99) with ALA, LA, AA, EPA and DHA (p<0.001) 
and marginal association with DPA (p=0.068). In the present 
study, rs174546 (in high LD with rs174537, r2=0.99), has been as-
sociated with ALA, LA, AA, DGLA levels post-supplementation, 
but not with LC n-3 FAs, as shown by others. However, this SNP 
was associated with post-supplementation Factor 2 that regroups 
several saturated FAs as one component.
Strengths and Limitations
This is a well-designed study to look at associations with genetic 
factors after a 6-week n-3 FA supplementation with sufficient 
statistical power to show significant associations. High doses of  
n-3 FAs were given to study participants and the compliance was 
really high as calculated by the remaining capsules from bottles 
returning and as shown by increased levels of  n-3 FAs into PPLs.
Recent evidence suggests that PPL FA pool may be more affected 
by recent fat consumption and that it would be more effective to 
look at FAs in RBCs especially in the context of  genetic studies 
[51]. FAs were also measured in RBCs in the present study, but 
only in 30 individuals. However, the combined levels of  EPA and 
DHA in PPLs correlated with levels from RBCs after the sup-
plementation (r=0.47, p=0.02) [52]. Thus, PCA were done using 
FAs measured in PPLs.
Conclusion
It is clear that each FA has its own particular effect on lipid metab-
olism. This study shows that not only polyunsaturated FAs alone 
could play a role in modulating plasma TG levels in response to a 
supplementation with n-3 FAs, but also that several FAs strongly 
correlated and regrouped as factors could be considered. These 
factors could potentially act as better biomarkers than FA levels 
alone measured in PPLs. Dissemination of  negative or positive 
responders to the n-3 FA supplementation may be more effec-
tive when looking at individuals scoring high to a specific FA pat-
tern rather than looking at FAs alone. Moreover, SNPs from the 
FADS gene cluster have the ability to interact with both FAs and/
or factors to possibly modulate TG levels.
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